OptimizeRx Corporation — FY 2012 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2012; it also reports selected fourth-quarter results. OptimizeRx provides digital healthcare marketing and patient-support tools, including SampleMD, which integrates prescription savings offers into physician workflows, and the OptimizeRx.com consumer portal. Management described a shift toward technology solutions and reported expansion of pharmaceutical programs and platform partnerships.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $2,048,699 | $1,111,520 |
| Operating expenses | $2,413,044 | $2,565,497 |
| Loss from operations | $(364,345) | $(1,453,977) |
| Net loss | $(363,976), or $(0.03) per share | $(2,120,762), or $(0.15) per share |
| Cash used in operating activities | $(624,033) | $(521,509) |
Revenue grew about 84% year over year. Operating expenses fell about 6%, with lower advertising, professional and consulting costs partly offset by higher salaries and stock-based compensation. The prior-year net loss included $958,641 of interest expense and $916,667 of debt-discount amortization; FY 2012 interest expense was $100. The filing does not provide gross profit or gross margin.
Management reported fourth-quarter 2012 revenue of $750,719 versus $325,910 in fourth-quarter 2011, and net income of $118,993 versus a net loss of $93,143. These quarterly figures are presented in the business discussion; separate quarterly financial statements are not included in the supplied text.
At year-end, cash and cash equivalents were $284,263 (down from $959,166); current assets were $969,219, current liabilities $679,945, and working capital $289,274. Total assets were $2,175,404 and stockholders’ equity was $1,495,459. Current liabilities included $570,000 payable to a related party. The balance sheet shows no conventional long-term debt. Operating cash use exceeded the net loss, with working-capital movements—including declines in accounts payable and deferred revenue—contributing to the outflow. Investing activities used $50,870, mainly for website development; no financing cash was raised in 2012.
Changes, outlook, and material matters
- Growth and execution: Management attributed revenue growth to SampleMD activity and manufacturer setup and integration fees. It reported programs involving 20 pharmaceutical and medical manufacturers, a new client dashboard, a SampleMD launch in Allscripts PRO, and integration work with HealthTronics. Allscripts access was constrained because clinicians had to activate the feature; management anticipated an opt-out change in the second quarter of 2013.
- Funding and liquidity risk: Management said available cash was sufficient for operations at the then-current level for the next 12 months, but not for its business goals without generating cash from sales and/or obtaining financing. The prior Vicis financing commitment had lapsed, and discussions about additional financing were not supported by a written agreement.
- Vicis arrangements: The company had 65 preferred shares outstanding. Series A and B preferred stock carry 10% cumulative dividends; the filing reports $500,000 of undeclared 2012 dividends. A January 2013 agreement gave the company an option, expiring December 31, 2013, to buy Vicis-held securities for $9 million, subject to terms including possible extinguishment if Vicis sells the securities first. The CEO was affiliated with Vicis, creating a related-party consideration.
- Legal and intellectual property: LDM Group sued the company in November 2012 alleging patent infringement; OptimizeRx said it would vigorously defend itself. In February 2013, OptimizeRx filed a patent-infringement suit against Physicians Interactive and related entities. The company reported receiving SampleMD patent No. 8,341,015 in fourth-quarter 2012 and filing two additional patent applications.
- Other risks: Two major customers together accounted for 52% of 2012 revenue (the filing’s wording does not clearly specify whether this is a combined share). The company described its stock as thinly traded OTC securities and warned that shareholders may have difficulty reselling shares. Healthcare fraud-and-abuse, privacy, security and regulatory requirements may affect the business.
- Management and controls: Shad Stastney became CEO under a January 2013 agreement providing $175,000 annual compensation and 2 million options at a $1.00 exercise price; the agreement requires salary to be accrued and deferred until at least January 1, 2014. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal controls. The financial statement audit opinion was unqualified.
- No formal financial guidance: The filing provides no quantified revenue, earnings or cash-flow guidance. Management’s outlook emphasized partnerships, integration and continued growth, subject to customer adoption and financing availability.
Important facts for investors to verify
- Reconcile the filing’s inconsistent loss figures: the business overview cites a $364,345 net loss, while the audited statements report a $363,976 net loss; $364,345 is the audited loss from operations.
- Verify the exact common shares outstanding: the balance sheet and one ownership disclosure report 14,232,496, while the cover and another ownership calculation cite 14,192,496 for March 2013.
- Assess cash runway and whether operating cash generation or committed financing is sufficient to fund planned growth; no additional Vicis financing agreement was in place.
- Review the $570,000 related-party payable, cumulative preferred dividends, the $9 million redemption option, and potential dilution from preferred conversions, warrants and the CEO’s proposed 2 million options.
- Evaluate the LDM patent claim, OptimizeRx’s infringement action, customer concentration, and whether the anticipated Allscripts opt-out change and other integrations actually expanded clinician access.